Wealthspire Advisors (New York)’s Vertex Pharmaceuticals VRTX Stock Holding History

Wealthspire Advisors (New York)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$566K	Buy	1,138 +243	+27%	+$108K	﹤0.01%	759
2026 Q1	$400K	Sell	895 -930	-51%	-$434K	﹤0.01%	646
2025 Q4	$827K	Buy	1,825 +1,382	+312%	+$596K	0.01%	471
2025 Q3	$173K	Sell	443 -438	-50%	-$183K	﹤0.01%	843
2025 Q2	$392K	Buy	881 +151	+21%	+$69.6K	﹤0.01%	602
2025 Q1	$354K	Sell	730 -19	-3%	-$8.85K	﹤0.01%	598
2024 Q4	$302K	Sell	749 -43	-5%	-$19.9K	﹤0.01%	642
2024 Q3	$368K	Buy	792 +159	+25%	+$76.4K	﹤0.01%	573
2024 Q2	$297K	Sell	633 -108	-15%	-$46.9K	﹤0.01%	545
2024 Q1	$310K	Sell	741 -228	-24%	-$96.4K	﹤0.01%	514
2023 Q4	$394K	Buy	969 +310	+47%	+$115K	0.01%	455
2023 Q3	$229K	Sell	659 -1	-0.2%	-$350	﹤0.01%	536
2023 Q2	$232K	Buy	+660	New	+$222K	﹤0.01%	498
2023 Q1	–	Sell	-833	Closed	-$241K	–	598
2022 Q4	$241K	Buy	+833	New	+$254K	﹤0.01%	505
2021 Q2	–	Sell	-2,714	Closed	-$583K	–	662
2021 Q1	$583K	Sell	2,714 -88	-3%	-$19.3K	0.01%	356
2020 Q4	$662K	Buy	2,802 +794	+40%	+$182K	0.02%	262
2020 Q3	$546K	Buy	2,008 +117	+6%	+$32.3K	0.03%	172
2020 Q2	$549K	Sell	1,891 -438	-19%	-$119K	0.04%	147
2020 Q1	$554K	Buy	2,329 +1,335	+134%	+$306K	0.02%	278
2019 Q4	$218K	Buy	+994	New	+$201K	0.02%	192
2019 Q1	–	Sell	-220	Closed	-$36K	–	779
2018 Q4	$36K	Buy	+220	New	+$38.1K	﹤0.01%	230

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Wealthspire Advisors (New York)'s VRTX Position: Q2 2026 in Review

Wealthspire Advisors (New York) increased its Vertex Pharmaceuticals (VRTX) stake by 27% in Q2 2026, buying an estimated $108K and bringing the position to 1,138 shares worth $566K. The position accounts for ﹤0.01% of the portfolio, ranked #759.

Wealthspire Advisors (New York) first reported a position in VRTX in Q4 2018 and has held it in 21 quarters since. The position peaked at $827K in Q4 2025. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

Wealthspire Advisors (New York) held 1,138 shares of Vertex Pharmaceuticals worth $566K as of Q2 2026.
Wealthspire Advisors (New York) bought 243 Vertex Pharmaceuticals shares in Q2 2026, an estimated $108K.
Vertex Pharmaceuticals made up ﹤0.01% of Wealthspire Advisors (New York)'s portfolio in Q2 2026, its #759 holding.
Wealthspire Advisors (New York) first reported a position in Vertex Pharmaceuticals in Q4 2018 and has held it in 21 quarters since.
Wealthspire Advisors (New York)'s Vertex Pharmaceuticals position peaked at $827K in Q4 2025.
1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Wealthspire Advisors (New York)'s 13F filing for Q2 2026, filed 11 Aug 2026.